IBRX

ImmunityBio Inc. (IBRX) | Rumor.io

ImmunityBio

IBRX

Attention (50-day avg)0.13%

Attention rank (50-day avg)#82

Bullish sentiment (50-day avg)79%

Price to earnings ratio-22.4

Market capitalization9B

Earnings per share-0.95

Dividend yield (TTM)—

Revenue (annual)113.3M

Net income (annual)-351.5M

Social

What share of all stock conversation is about IBRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.28% -0.06	0.18% -0.02	0.13% +0.03	0.18% +0.12

Sep 30

Recent positive data on Anktiva from ImmunityBio, Inc. (IBRX) is a significant derisking event, with randomized controlled data supporting the company's claims.
Market analysts believe IBRX's stock price may break through resistance at $9.5 and potentially reach $10.25-$11, or double spike and return to $8.25-$8.5.
The quality of the IBRX community's discussion is high, with many users expressing enthusiasm for the company's prospects, citing its potential for "real fun" and strong news on the horizon.

Generated by AI

Sentiment

Of the messages about IBRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	88.62% -2.33	86.29% +4.74	81.93% +4.93	77.91% +1.86
Bearish	11.38% +2.33	13.71% -4.74	18.07% -4.93	22.09% -1.86

Bullish· Sep 29

The company's sequential revenue is doubling, and non-dilutive financing is providing a strong foundation for growth.
The asset's multi-front pipeline is "exploding into fruition," with imminent fundamental catalysts that are expected to drive a "violent squeeze" and a significant price increase.
The asset's overseas sales are knocking on the door, and 2027 sales are expected to be strong, with the potential for significant revenue growth and a substantial increase in stock price.

Bearish· Sep 29

The company's stock has been subject to manipulation by short sellers and market makers, leading to significant losses for investors who held on to their shares despite the challenges.
The stock's price has been consistently dropping over time, with some investors expressing frustration and anger at the lack of progress and the perceived manipulation by short sellers.
The stock's price is highly volatile, with some investors warning of a possible decline in the stock's price, citing the example of a rival biotech company's stock price plummeting by 40% overnight.

Generated by AI

Topics

Of the messages about IBRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Macro	0%	2.79%	0.87%	20.74%
Announcements	56.86%	60.61%	70.27%	44.12%
Technical Analysis	43.14%	34.2%	24.16%	11%
Earnings	0%	0%	0%	2.78%
Analysts	0%	2.11%	0.6%	18.81%
Controversies	0%	0.29%	4.09%	2.55%

Analysts· Mar 4

Piper Sandler raised the price target for ImmunityBio (IBRX) to $12 from $7, maintaining an Overweight rating, based on strong commercial momentum for its bladder cancer drug ANKTIVA.
H.C. Wainwright maintained a Buy rating for ImmunityBio (IBRX) and increased its price target to $15 from $10, citing the company's commercial and strategic progress with ANKTIVA.
Analysts have been optimistic about ImmunityBio's prospects, with multiple firms issuing positive ratings and price target increases, citing the company's strong revenue growth and potential for continued expansion.

Announcements· Sep 15

Dr. Patrick Soon-Shiong, ImmunityBio's controlling shareholder, has joined the board of PDS Biotech, a micro-cap company, and led a $22.3 million investment in the company through Nant Capital.
The investment, which includes a one-year exclusive negotiating window for PDS Biotech's lead HPV-targeted immunotherapy, PDS0101, is expected to unlock significant pipeline synergies for ImmunityBio.
The deal also includes a potential milestone payment upon joint submission of Phase 3 for PDS0301, an immunocytokine program for solid tumors, which could allow ImmunityBio to negotiate exclusive rights to PDS0101.

Controversies· Mar 24

The FDA issued a warning letter to ImmunityBio ($IBRX) for making "false and misleading" claims about its ANKTIVA bladder cancer treatment.
ImmunityBio's founder, Patrick Soon-Shiong, has been accused of misrepresenting results from Anktiva's bladder cancer trials and interacting with FDA officials inappropriately.
The FDA's warning letter has sparked controversy and speculation about potential lawsuits, with some commentators suggesting that ImmunityBio may file a lawsuit against the FDA.

Technical Analysis· Jun 26

$IBRX has been in a trading range for 3 months, and a breakout above it could be a bullish sign.
The stock has shown improving price structure, with buyers stepping in and a strengthening technical picture.
$IBRX has broken above recent resistance, closed at the high of the day, and finished nearly 12% higher on heavy volume, indicating positive technical signals.

Generated by AI

Community

Of the messages about IBRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	84.14%	88.35%	88.36%	67.56%
Newcomers	15.86%	11.65%	11.64%	32.44%

Regulars· Sep 30

The release of positive data from Anktiva, a major derisking/rerating event for ImmunityBio, is a significant development for the company.
The reluctance of the market to let ImmunityBio's stock fade suggests ongoing interest and optimism from regular participants.
The successful defense against a large-scale short-selling attempt by Dr. Soon-Shiong has been praised, with some calling for a case study on the legality and ethics of the shorts' actions.

Newcomers· Sep 29

Newcomers to $IBRX are focusing on the company's unique mechanism (IL-15 superagonist) and its potential to revolutionize cancer treatment, citing its global approvals and multiple pipeline shots on goal.
The newcomers are also discussing the company's strong revenue growth, with some noting its triple-digit YoY increase and the potential for explosive growth in the future.
Others are highlighting the company's solid YTD chart and the potential for a breakout, with some wondering if the stock will return to its 2021 levels and others speculating about the company's future performance based on its technical analysis.

Generated by AI

News

ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%

7d agoYahoo Finance

Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode

Soon-Shiong owned 65.5% of ImmunityBio as of its April proxy record date.

9d agoYahoo Finance

ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

12d agoYahoo Finance

ImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention?

Nant Capital’s investment of up to $22.3 million in a PIPE into PDS Biotech, along with Patrick Soon Shiong’s new board seat there, pushed ImmunityBio (NasdaqGS:IBRX) up 6% on Monday and sharpened focus on his broader immunotherapy plans. ImmunityBio’s share price has cooled slightly in the very short term, with a 1-day share price return of 2.75% and a 7-day share price return of 1.81%. However, the 30-day and 90-day share price returns of 7.53% and 16.45% suggest momentum is still building...

14d agoYahoo Finance

IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet

15d agoYahoo Finance

SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck

ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.

16d agoYahoo Finance

Also Discussed

Investors talking about IBRX also mention

#	Name	Attention
1	Brand Engagement Network Inc.BNAI	0%+0
2	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
3	Candel Therapeutics, Inc.CADL	0.02%+0.01
4	EON Resources Inc. Class A Common StockEONR	0%0
5	BeOne Medicines Ltd. American Depositary SharesONC	0%0
6	Revolution Medicines, Inc.RVMD	0.01%-0.01
7	MiNK Therapeutics, Inc.INKT	0%new
8	SELLAS Life Sciences Group, Inc.SLS	0.56%-0.06
9	Replimune Group, Inc.REPL	0%0
10	Telix Pharmaceuticals Limited American Depositary SharesTLX	0%new

ImmunityBio Inc.

Healthcare
Biotechnology

ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company also works on additional biologic platforms, including cytokine fusion proteins, DNA and vaccine vectors, NK-cell therapies, and other immunomodulators for cancer and infectious diseases. ImmunityBio’s products and research programs are aimed at addressing unmet needs in oncology and infectious disease treatment through immune-based approaches. Headquartered in San Diego, California, ImmunityBio operates as a commercial-stage company with a focus on bringing biologic therapies from development into clinical use.

Website

Location

3530 John Hopkins Court

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about IBRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.28% -0.06	0.18% -0.02	0.13% +0.03	0.18% +0.12

Sep 30

Recent positive data on Anktiva from ImmunityBio, Inc. (IBRX) is a significant derisking event, with randomized controlled data supporting the company's claims.
Market analysts believe IBRX's stock price may break through resistance at $9.5 and potentially reach $10.25-$11, or double spike and return to $8.25-$8.5.
The quality of the IBRX community's discussion is high, with many users expressing enthusiasm for the company's prospects, citing its potential for "real fun" and strong news on the horizon.

Generated by AI

Sentiment

Of the messages about IBRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	88.62% -2.33	86.29% +4.74	81.93% +4.93	77.91% +1.86
Bearish	11.38% +2.33	13.71% -4.74	18.07% -4.93	22.09% -1.86

Bullish· Sep 29

The company's sequential revenue is doubling, and non-dilutive financing is providing a strong foundation for growth.
The asset's multi-front pipeline is "exploding into fruition," with imminent fundamental catalysts that are expected to drive a "violent squeeze" and a significant price increase.
The asset's overseas sales are knocking on the door, and 2027 sales are expected to be strong, with the potential for significant revenue growth and a substantial increase in stock price.

Bearish· Sep 29

The company's stock has been subject to manipulation by short sellers and market makers, leading to significant losses for investors who held on to their shares despite the challenges.
The stock's price has been consistently dropping over time, with some investors expressing frustration and anger at the lack of progress and the perceived manipulation by short sellers.
The stock's price is highly volatile, with some investors warning of a possible decline in the stock's price, citing the example of a rival biotech company's stock price plummeting by 40% overnight.

Generated by AI

Topics

Of the messages about IBRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Macro	0%	2.79%	0.87%	20.74%
Announcements	56.86%	60.61%	70.27%	44.12%
Technical Analysis	43.14%	34.2%	24.16%	11%
Earnings	0%	0%	0%	2.78%
Analysts	0%	2.11%	0.6%	18.81%
Controversies	0%	0.29%	4.09%	2.55%

Analysts· Mar 4

Piper Sandler raised the price target for ImmunityBio (IBRX) to $12 from $7, maintaining an Overweight rating, based on strong commercial momentum for its bladder cancer drug ANKTIVA.
H.C. Wainwright maintained a Buy rating for ImmunityBio (IBRX) and increased its price target to $15 from $10, citing the company's commercial and strategic progress with ANKTIVA.
Analysts have been optimistic about ImmunityBio's prospects, with multiple firms issuing positive ratings and price target increases, citing the company's strong revenue growth and potential for continued expansion.

Announcements· Sep 15

Dr. Patrick Soon-Shiong, ImmunityBio's controlling shareholder, has joined the board of PDS Biotech, a micro-cap company, and led a $22.3 million investment in the company through Nant Capital.
The investment, which includes a one-year exclusive negotiating window for PDS Biotech's lead HPV-targeted immunotherapy, PDS0101, is expected to unlock significant pipeline synergies for ImmunityBio.
The deal also includes a potential milestone payment upon joint submission of Phase 3 for PDS0301, an immunocytokine program for solid tumors, which could allow ImmunityBio to negotiate exclusive rights to PDS0101.

Controversies· Mar 24

The FDA issued a warning letter to ImmunityBio ($IBRX) for making "false and misleading" claims about its ANKTIVA bladder cancer treatment.
ImmunityBio's founder, Patrick Soon-Shiong, has been accused of misrepresenting results from Anktiva's bladder cancer trials and interacting with FDA officials inappropriately.
The FDA's warning letter has sparked controversy and speculation about potential lawsuits, with some commentators suggesting that ImmunityBio may file a lawsuit against the FDA.

Technical Analysis· Jun 26

$IBRX has been in a trading range for 3 months, and a breakout above it could be a bullish sign.
The stock has shown improving price structure, with buyers stepping in and a strengthening technical picture.
$IBRX has broken above recent resistance, closed at the high of the day, and finished nearly 12% higher on heavy volume, indicating positive technical signals.

Generated by AI

Community

Of the messages about IBRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	84.14%	88.35%	88.36%	67.56%
Newcomers	15.86%	11.65%	11.64%	32.44%

Regulars· Sep 30

The release of positive data from Anktiva, a major derisking/rerating event for ImmunityBio, is a significant development for the company.
The reluctance of the market to let ImmunityBio's stock fade suggests ongoing interest and optimism from regular participants.
The successful defense against a large-scale short-selling attempt by Dr. Soon-Shiong has been praised, with some calling for a case study on the legality and ethics of the shorts' actions.

Newcomers· Sep 29

Newcomers to $IBRX are focusing on the company's unique mechanism (IL-15 superagonist) and its potential to revolutionize cancer treatment, citing its global approvals and multiple pipeline shots on goal.
The newcomers are also discussing the company's strong revenue growth, with some noting its triple-digit YoY increase and the potential for explosive growth in the future.
Others are highlighting the company's solid YTD chart and the potential for a breakout, with some wondering if the stock will return to its 2021 levels and others speculating about the company's future performance based on its technical analysis.

Generated by AI

ImmunityBio

Social

Sep 30

Bullish· Sep 29

Bearish· Sep 29

Analysts· Mar 4

Announcements· Sep 15

Controversies· Mar 24

Technical Analysis· Jun 26

Regulars· Sep 30

Newcomers· Sep 29

ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%

Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode

ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?

ImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention?

IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet

SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck

Also Discussed

ImmunityBio Inc.

Company Information

Location

ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%

Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode

ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?

ImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention?

IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet

SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck

Also Discussed

Social

Sep 30

Bullish· Sep 29

Bearish· Sep 29

Analysts· Mar 4

Announcements· Sep 15

Controversies· Mar 24

Technical Analysis· Jun 26

Regulars· Sep 30

Newcomers· Sep 29